Immune check-point in cervical cancer

F. De Felice; Claudia Marchetti; I. Palaia; R. Ostuni; L. Muzii; V. Tombolini; P. Benedetti Panici

doi:10.1016/j.critrevonc.2018.06.006

Immune check-point in cervical cancer

F. De Felice
, Claudia Marchetti
, I. Palaia
, R. Ostuni
, L. Muzii
, V. Tombolini
, P. Benedetti Panici

University of Rome La Sapienza

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.

Lingua originale	Inglese
pagine (da-a)	40-43
Numero di pagine	4
Rivista	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume	129
DOI	https://doi.org/10.1016/j.critrevonc.2018.06.006
Stato di pubblicazione	Pubblicato - 2018

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

CTLA-4
Cervical cancer
Immune check-point
Immunotherapy
Ipilimumab
Nivolumab
PD-1
Pembrolizumab

Accesso al documento

10.1016/j.critrevonc.2018.06.006

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{9446ff3886c94d7ca426567233d982e1,

title = "Immune check-point in cervical cancer",

abstract = "Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.",

keywords = "CTLA-4, Cervical cancer, Immune check-point, Immunotherapy, Ipilimumab, Nivolumab, PD-1, Pembrolizumab, CTLA-4, Cervical cancer, Immune check-point, Immunotherapy, Ipilimumab, Nivolumab, PD-1, Pembrolizumab",

author = "\{De Felice\}, F. and Claudia Marchetti and I. Palaia and R. Ostuni and L. Muzii and V. Tombolini and \{Benedetti Panici\}, P.",

year = "2018",

doi = "10.1016/j.critrevonc.2018.06.006",

language = "English",

volume = "129",

pages = "40--43",

journal = "CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY",

issn = "1040-8428",

publisher = "-NEW YORK, USA, NY: ELSEVIER SCIENCE INC -Boca Raton, Fla.: CRC Press.",

}

TY - JOUR

T1 - Immune check-point in cervical cancer

AU - De Felice, F.

AU - Marchetti, Claudia

AU - Palaia, I.

AU - Ostuni, R.

AU - Muzii, L.

AU - Tombolini, V.

AU - Benedetti Panici, P.

PY - 2018

Y1 - 2018

N2 - Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.

AB - Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.

KW - CTLA-4

KW - Cervical cancer

KW - Immune check-point

KW - Immunotherapy

KW - Ipilimumab

KW - Nivolumab

KW - PD-1

KW - Pembrolizumab

KW - CTLA-4

KW - Cervical cancer

KW - Immune check-point

KW - Immunotherapy

KW - Ipilimumab

KW - Nivolumab

KW - PD-1

KW - Pembrolizumab

UR - http://hdl.handle.net/10807/203893

U2 - 10.1016/j.critrevonc.2018.06.006

DO - 10.1016/j.critrevonc.2018.06.006

M3 - Article

SN - 1040-8428

VL - 129

SP - 40

EP - 43

JO - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

JF - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

ER -

Immune check-point in cervical cancer

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo